Medical Foods – the emerging role of personalized medicine
Our products are unusual. In part because medical foods are a relatively new concept in the marketplace. Traditional medicine is approached as a "trial and error" method and is usually directed against the particular symptoms of the patient. Our approach is to look deeper into the underlying causes of their disease and/or medical condition. In so doing, we find that patients can often be grouped according to their genetic background. Such characteristics may reveal a predisposition to metabolic imbalances, enzyme deficiencies or various physiologic triggers that complicate their disease or condition. Pamlab believes that the future of pharmacology will become more personalized according to each patients genetic predisposition rather than a "one-size fits all" approach.
Key Disease States
Our research in medical foods has lead us to explore solutions for the distinct nutritional needs that some patients have in particular disease states. In most cases, the patient seeking treatment for his/her condition has a genetically-based inborn error of metabolism that has created a need for him/her to require certain nutrients to correct his/her metabolic imbalance.
Diabetes/Diabetic Peripheral Neuropathy
Metanx® is an orally administered prescription medical food for the dietary management of endothelial dysfunction in patients with diabetic peripheral neuropathy.
Deplin® is a medical food dispensed by prescription for the clinical dietary management of the metabolic imbalances associated with depression and schizophrenia. Use under medical supervision.
NeevoDHA® is a food for special dietary use in women who are pregnant or lactacting.
* 1.13mg L-methylfolate (calculated as L-methyltetrahydrofolic acid) is the molar quivalent of 1.0mg folic acid.
** Docosahexaenoic acid (DHA) from an algal source.
CerefolinNAC® is an orally administered prescription medical food for use only under medical supervision for the dietary management of certain metabolic processes identified with mild cognitive impairment.
New Product Pipeline
Our Research and Development staff is in continuous review of new pharmaceutical products to be launched or acquired. Our sales force includes both dedicated outside sales representatives as well as multiple inside sales teams. Our sales force gives us a national presence while our inside sales force provides physician support and online education. The resulting infrastructure provides optimum flexibility for both national new product roll-outs as well as specialty or niche product introductions.
To anticipate our future expansion of products and new indications, feel free to peruse our R&D website which lists all active IRB-supervised projects as well as our recently completed clinical studies.